Glenmark Pharma Valuation Multiples

Glenmark Pharma Overview

About Glenmark Pharma

Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.

Founded

1977

HQ

Employees

13.5K

Website

glenmarkpharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $2B

EBITDA: $516M

EV

$6B

Valuation Multiples

Multiples.vc

Start free trial

Glenmark Pharma Financials

Glenmark Pharma reported last 12-month revenue of $2B and EBITDA of $516M.

In the same LTM period, Glenmark Pharma generated $1B in gross profit, $516M in EBITDA, and $312M in net income.

Glenmark Pharma P&L

In the most recent fiscal year, Glenmark Pharma reported revenue of $2B and EBITDA of $276M.

Glenmark Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Glenmark Pharma Stock Performance

Glenmark Pharma has current market cap of $7B, and enterprise value of $6B.

Glenmark Pharma's stock price is $23.51.

Glenmark Pharma Valuation Multiples

Glenmark Pharma trades at 3.5x EV/Revenue multiple, and 12.5x EV/EBITDA.

Glenmark Pharma Financial Valuation Multiples

As of April 10, 2026, Glenmark Pharma has market cap of $7B and EV of $6B.

Equity research analysts estimate Glenmark Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Glenmark Pharma has a P/E ratio of 21.3x.

Glenmark Pharma Margins & Growth Rates

Glenmark Pharma's revenue in the last 12 month declined by (7%).

Glenmark Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Glenmark Pharma's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Glenmark Pharma's rule of X is 24% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Glenmark Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Glenmark Pharma M&A Activity

Glenmark Pharma acquired XXX companies to date.

Last acquisition by Glenmark Pharma was on XXXXXXXX, XXXXX. Glenmark Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Glenmark Pharma Investment Activity

Glenmark Pharma invested in XXX companies to date.

Glenmark Pharma made its latest investment on XXXXXXXX, XXXXX. Glenmark Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).